Blog
Pinatuzumab Biosimilar: Advancing CD22-Targeted Therapy in B-Cell Malignancies
Pinatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD22, a cell surface marker highly expressed on malignant B cells. It delivers a potent cytotoxic agent directly to CD22
…
12th Dec 2024